{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T02:04:16Z","timestamp":1773021856321,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T00:00:00Z","timestamp":1519344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.vaccine.2018.02.085","type":"journal-article","created":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T15:00:07Z","timestamp":1521817207000},"page":"2356-2363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study"],"prefix":"10.1016","volume":"36","author":[{"given":"Nicola P.","family":"Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Habanec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Kosina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmish R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devayani","family":"Kolhe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjan","family":"Hezareh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Van der Wielen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.02.085_b0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40121-016-0107-0","article-title":"Meningococcal vaccinations","volume":"5","author":"Crum-Cianflone","year":"2016","journal-title":"Infectious Diseases Therapy"},{"key":"10.1016\/j.vaccine.2018.02.085_b0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11910-015-0524-6","article-title":"Invasive meningococcal disease in the 21st century-an update for the clinician","volume":"15","author":"Dwilow","year":"2015","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.vaccine.2018.02.085_b0015","unstructured":"WHO. Meningococcal vaccines: WHO position paper. Weekly Epidemiological Record. 2011;47:521\u201340."},{"key":"10.1016\/j.vaccine.2018.02.085_b0020","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1749-6632.2009.04633.x","article-title":"Clinical significance of complement deficiencies","volume":"1173","author":"Pettigrew","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2018.02.085_b0025","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/CMR.00048-09","article-title":"Infections of people with complement deficiencies and patients who have undergone splenectomy","volume":"23","author":"Ram","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2018.02.085_b0030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/bjs.6106","article-title":"Vaccination of asplenic or hyposplenic adults","volume":"95","author":"Mourtzoukou","year":"2008","journal-title":"Br J Surg"},{"key":"10.1016\/j.vaccine.2018.02.085_b0035","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged \u226510 years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices, 2015","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.02.085_b0040","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2018.02.085_b0045","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1128\/IAI.69.12.7583-7587.2001","article-title":"Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharides","volume":"69","author":"Breukels","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.02.085_b0050","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1086\/314582","article-title":"Normal IgG and impaired IgM responses to polysaccharide vaccines in asplenic patients","volume":"179","author":"Molrine","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.085_b0055","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/IAI.72.1.332-337.2004","article-title":"Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals","volume":"72","author":"Balmer","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.02.085_b0060","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1016\/j.vaccine.2011.03.080","article-title":"Natural and vaccine-induced immunity to Neisseria meningitidis serogroup C in asplenic patients with \u03b2-thalassemia","volume":"29","author":"Spoulou","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.085_b0065","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3109\/00365549209054649","article-title":"Antibody response to a Haemophilus influenzae type b polysaccharide tetanus toxoid conjugate vaccine in splenectomized children and adolescents","volume":"24","author":"Kristensen","year":"1992","journal-title":"Scand J Infect Dis."},{"key":"10.1016\/j.vaccine.2018.02.085_b0070","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1542\/peds.2007-0018","article-title":"Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life","volume":"121","author":"Adamkiewicz","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.02.085_b0075","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1086\/516781","article-title":"Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine","volume":"44","author":"Halasa","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.085_b0080","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1084\/jem.20022020","article-title":"Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen","volume":"197","author":"Kruetzmann","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.02.085_b0085","first-page":"527","article-title":"Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013","volume":"63","author":"MacNeil","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.02.085_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2016.1143157","article-title":"Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MENACWY-TT, Nimenrix\u2122): a review of its immunogenicity, safety, co-administration, and antibody persistence","volume":"12","author":"Assaf-Casals","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.02.085_b0095","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1586\/erv.12.32","article-title":"MenACWY-TT vaccine for active immunization against invasive meningococcal disease","volume":"11","author":"Papaevangelou","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.02.085_b0100","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2165\/11209580-000000000-00000","article-title":"Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix\u2122)","volume":"72","author":"Croxtall","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2018.02.085_b0105","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(10)61493-6","article-title":"Post-splenectomy and hyposplenic states","volume":"378","author":"Di Sabatino","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2018.02.085_b0110","first-page":"699","article-title":"ACIP update: 2 new recommendations for meningococcal vaccine","volume":"59","author":"Campos-Outcalt","year":"2010","journal-title":"J Fam Pract"},{"key":"10.1016\/j.vaccine.2018.02.085_b0115","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World medical association declaration of Helsinki","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.02.085_b0120","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.02.085_b0125","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.02.085_b0130","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1016\/j.vaccine.2015.07.019","article-title":"Serum bactericidal antibody assays \u2013 the role of complement in infection and immunity","volume":"33","author":"McIntosh","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.085_b0135","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection-serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.085_b0140","first-page":"1016","article-title":"Inadvertent misadministration of meningococcal conjugate vaccine-United States, June-August 2005","volume":"55","author":"Centers for Disease Control and Prevention","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.02.085_b0145","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/JCM.32.6.1475-1482.1994","article-title":"Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay","volume":"32","author":"Gheesling","year":"1994","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.02.085_b0150","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/00003495-199855030-00003","article-title":"Meningococcal vaccines Current status and future possibilities","volume":"55","author":"Peltola","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2018.02.085_b0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0092-1157(83)80038-9","article-title":"A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera","volume":"11","author":"Melville-Smith","year":"1983","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2018.02.085_b0160","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.02.085_b0165","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":"A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children","volume":"28","author":"Knuf","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.085_b0170","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/INF.0b013e31820e6e02","article-title":"Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile","volume":"30","author":"Memish","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.02.085_b0175","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00431-012-1924-0","article-title":"Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2\u201310-year-old children: results of an open, randomised, controlled study","volume":"172","author":"Knuf","year":"2013","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2018.02.085_b0180","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.4161\/hv.22165","article-title":"A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2\u201310 years","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.02.085_b0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jpids\/pit058","article-title":"Comparison of the safety and immunogenicity of a novel quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine and a marketed quadrivalent meningococcal ACWY-diphtheria toxoid conjugate vaccine in healthy individuals 10\u201325 years of age","volume":"3","author":"Halperin","year":"2013","journal-title":"J Pediatr Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2018.02.085_b0190","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0b013e31828693c5","article-title":"One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children","volume":"32","author":"Klein","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.02.085_b0195","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/INF.0000000000000630","article-title":"Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro","volume":"34","author":"Frota","year":"2015","journal-title":"Brazil. Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.02.085_b0200","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/adc.86.3.215","article-title":"Investigation for complement deficiency following meningococcal disease","volume":"86","author":"Hoare","year":"2002","journal-title":"Arch Dis Child"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18302846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18302846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T02:35:05Z","timestamp":1604025305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18302846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":40,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0264410X18302846"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.085","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}